2005
DOI: 10.1007/s00280-005-0037-0 View full text |Buy / Rent full text
|
|

Abstract: Increased [F-18]FAU retention was shown in the breast tumors but not in colorectal tumors. The increased retention of FAU in the breast compared to bone marrow indicates that FAU may be useful as an unlabeled antineoplastic agent. The low retention in the marrow indicates that unlabeled FAU might lead to little marrow toxicity; however, the images were not of high contrast to consider FAU for diagnostic clinical imaging.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
16
0

Year Published

2007
2007
2012
2012

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

1
16
0
Order By: Relevance
“…Previous studies with 18 F-FAU have found the tracer to be uniformly distributed throughout the body, with a low uptake in the marrow (21). Similar contrast was also seen in human subjects (3). This literature further supports the finding that the uptake we have seen in the marrow of normal dogs is primarily due to 18 F-FIAU and not due to 18 F-FAU.…”
Section: Discussionsupporting
“…Briefly, blood samples were drawn at 1,2,3,4,5,6,7,9,11,15,21,30,40,50,60,90,120, and 150 min after injection, and urine samples were collected at 60 and 120 min to measure the metabolite concentration. Total blood and urine activity was measured in a NaI(Tl) well counter crosscalibrated with the PET camera (Cobra II; PerkinElmer Life Sciences Inc.).…”
Section: Blood and Tissue Analysismentioning
See 1 more Smart Citation
“…Another example of a drug that has used information from subtherapeutic dosing to assist in the design of a more robust phase I clinical trial is FAU [1-(2′-deoxy-2′-fluoro-beta-D: -arabinofuranosyl) uracil]. Originally, 18 F-labeled FAU was evaluated as an alternative positron emission tomography (PET) imaging agent (41). The availability of 18 F-FAU enabled the design of a phase I clinical trial of nonradioactive FAU as a suicide prodrug with correlative studies emphasizing PET imaging with 18 F-FAU to measure incorporation of drug into tumor and normal tissues.…”
Section: Trial Designmentioning
“…In some situations, studies are looking at whether or not a particular receptor is present; other studies are mainly looking at the delivery of the agent, and in some situations, studies are looking at whether the agent is taken up and retained within the tumor [4].…”
mentioning